Stockhead Presents: Vital Signs

Stockhead
  • 0.0 (0)
  • Investing

Stockhead's Health and Biotech reporter Nadine McGrath is joined by industry experts to discuss healthcare and biotechnology investments. Hear insights from leaders, innovators, and investors who are shaping the future of healthcare. Whether you're an investor looking for the next big opportunity, a professional in the field, or simply curious about the advancements transforming healthcare, Vital Signs provides valuable insights and fascinating information. Hear about cutting-edge technologies, groundbreaking research, and the financial strategies driving success in the biotech world. Subscribe now to be a part of the exciting landscape of health and biotech investment.

  1. Aug 28

    Inside Prescient Therapeutics' fight against a rare blood cancer

    Stockhead's Vital Signs sits down with Prescient Therapeutics (ASX:PTX) CEO James McDonnell to unpack PTX-100, a first-in-class cancer therapy targeting the RAS pathway implicated in 22% of cancers. From the science behind the drug to its phase two trial in cutaneous T-cell lymphoma, a $580 million validating licensing deal, and the milestones ahead, McDonnell breaks down what investors should be watching next. Learn more about your ad choices. Visit megaphone.fm/adchoices

  2. Mar 9

    MASTRR study redefining regenerative healing - Aroa Biosurgery (ASX:ARX)

    In today's episode, Nadine speaks to Dr. Adam Young of Aroa Biosurgery (ASX:ARX) Learn more about your ad choices. Visit megaphone.fm/adchoices

  3. Mar 9

    Vital Signs Podcast: Health Food Symmetry

    In today's episode, Nadine speaks to Gordon Edwards, CEO of Health Food Symmetry Learn more about your ad choices. Visit megaphone.fm/adchoices

  4. 10/21/2025

    Redefining hearing health with personalised sound technology-Audeara (ASX:AUA)

    In today's episode, Nadine speaks to Dr. James Fielding, CEO of Audeara (ASX:AUA) Learn more about your ad choices. Visit megaphone.fm/adchoices

  5. 07/01/2025

    Prescient eyes FDA fast track for cancer drug treatment | Prescient Therapeutics (ASX:PTX)

    In today's episode, Nadine speaks to James McDonnell, CEO of Prescient Therapeutics (ASX:PTX) Learn more about your ad choices. Visit megaphone.fm/adchoices

  6. 06/15/2025

    Heartfelt & WiSE: EBR embarks on new growth chapter after US FDA approval

    In today's episode, Nadine speaks to John McCutcheon President & CEO of EBR Systems (ASX:EBR) Learn more about your ad choices. Visit megaphone.fm/adchoices

  7. 05/29/2025

    Breakthrough brain scanning technology overcoming diagnostic hurdles - Compumedics (ASX:CMP)

    In today's episode, Nadine speaks to Gordon Haid, Global Neuro-Imaging Business Director  of Compumedics (ASX:CMP) Learn more about your ad choices. Visit megaphone.fm/adchoices

  8. 03/25/2025

    Clever Culture Systems' shift to big pharma clients is perfect prescription - Clever Culture Systems (ASX:CC5)

    In today's episode, Nadine speaks to Brent Barnes, CEO and Managing Director of Clever Culture Systems (ASX:CC5) Learn more about your ad choices. Visit megaphone.fm/adchoices

See All (13)

About

Stockhead's Health and Biotech reporter Nadine McGrath is joined by industry experts to discuss healthcare and biotechnology investments. Hear insights from leaders, innovators, and investors who are shaping the future of healthcare. Whether you're an investor looking for the next big opportunity, a professional in the field, or simply curious about the advancements transforming healthcare, Vital Signs provides valuable insights and fascinating information. Hear about cutting-edge technologies, groundbreaking research, and the financial strategies driving success in the biotech world. Subscribe now to be a part of the exciting landscape of health and biotech investment.

Information